Cerenome CNSY 深 滬
等待開盤 11-04 09:30:00 美东时间
1.30
-0.410
-23.98%
華盛通- 最 高4.25
- 今 開1.70
- 成交量 2901.73万股
- 最 低 1.16
- 昨 收 1.71
- 總市值 986.65万
- 52周最高 18.885
- 市盈率 靜 --
- 換手率 382.33%
- 52周最低 1.16
- 委 比 46.38%
- 總股本 758.96万
- 歷史最高 8583.75
- 量 比 614.34
- 振 幅 180.70%
- 歷史最低 1.16
- 每 手 1
- 風險率 4.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
Cerenome, Inc. has completed enrollment in the Phase 2 ReSPECT-GBM study evaluating REYOBIQ™ for recurrent glioblastoma. The trial enrolled 32 patients at the recommended Phase 2 dose, with topline data expected in mid-2027. REYOBIQ bypasses the blood-brain barrier via convection-enhanced delivery, delivering targeted radiation to tumors. Interim Phase 2 data showed a 63% improvement in median overall survival (13 months vs. 8 months) compared to...
10-29 11:30
Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational targeted r...
10-21 19:31
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Cerenome, Inc. announced new preclinical data showing that REYOBIQ™, its targeted radiotherapeutic, exhibits immunomodulatory properties in ovarian cancer models. The study revealed that REYOBIQ induces tumor injury, activates DNA-damage and immune response pathways, and reduces immunosuppressive signals. Combination with anti-PD-1 checkpoint inhibitors enhanced antitumor activity, improving survival and reducing tumor burden. These findings sugg...
10-21 11:30
Cerenome Updates Investor Presentation on CNS Oncology Strategy
An update from Cerenome ( ($CNSY) ) is now available. On September 30, 2026, Ce...
10-02 19:58
美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
Lake Street Maintains Buy on Cerenome, Lowers Price Target to $31
Lake Street analyst Chad Messer maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $50 to $31.
10-02 00:06
Cerenome Anticipates $1.55M In Payer Billings In Q3
Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test (TCE Test) and the expansion o...
09-30 19:33
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
Cerenome subsidiary CNSide Diagnostics signed an agreement with Blue Cross Blue Shield of Michigan (BCBSM) to provide its CNSide® CSF Tumor Cell Enumeration assay, effective September 1, 2026. This expands coverage to approximately 158 million commercial and Medicare Advantage lives, supporting patient access and advancing the company's reimbursement strategy. The CNSide® assay aids in diagnosing and monitoring leptomeningeal metastases, with ove...
09-22 11:30
美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
Cerenome Enters Financing Agreement With 3i Fund For Senior Secured Facility Of Up To $20M With Royalty-Based Repayments
Under the agreement, the Company received initial funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the scale-up of the Company’s proprietary laboratory-developed tests, particularly its CNSide® cerebrospinal fluid ("CSF") assa...
09-10 19:17
